Analyst firms · Leerink Partners · REPL

Leerink Partners REPL price target and rating history

Replimune Group Inc. (REPL) · Health Care

Leerink Partners rates Replimune Group Inc. (REPL) Outperform with a $17 price target, as of its latest action on Aug 4, 2026. It has published 6 rating actions on REPL since August 2021, including 2 upgrades and 2 downgrades. Across 5 firms with a REPL price target in the last 12 months, the median target is $12. Leerink Partners's $17 is 42% above that.

Current rating
Outperform
Price target
$17
Median target, all firms
$12
Actions on REPL
6

Leerink Partners price target on REPL

$55$29$220222023202420252026
Leerink Partners price target on REPL, each point a stated target, August 2021 to August 2026.

Every Leerink Partners rating on REPL

How other firms rate REPL

Each firm's latest rating and stated target in the last 12 months.

FirmRatingPrice targetDate
WedbushOutperform$12Aug 7, 2026
Leerink PartnersOutperform$17Aug 4, 2026
Cantor FitzgeraldOverweightJul 31, 2026
BMO Capital MarketsOutperform$16Jun 30, 2026
JefferiesHold$2Apr 13, 2026
H.C. WainwrightSellApr 13, 2026
Piper SandlerNeutral$4Apr 10, 2026

Questions about Leerink Partners and REPL

What is Leerink Partners's price target for REPL?
Leerink Partners's latest stated price target for Replimune Group Inc. (REPL) is $17, from its action on Aug 4, 2026.
What is Leerink Partners's rating on REPL?
Leerink Partners rates REPL Outperform, a bullish rating, as of Aug 4, 2026.
When did Leerink Partners last change its view on REPL?
On Aug 4, 2026, Leerink Partners upgrades to Outperform from Market Perform, price target $17.
How does Leerink Partners's REPL target compare with other analysts?
Across 5 firms with a REPL price target in the last 12 months, the median target is $12. Leerink Partners's $17 is 42% above that.

More REPL rating histories

All Leerink Partners ratingsREPL news and filingsEvery analyst firm

From rating actions in the Quantisnow feed. A target holds until the firm states a new one; a reiteration with no target keeps the last one. Not investment advice.